Mustang Bio (MBIO) vs Onconetix (ONCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Onconetix is the larger company by market cap ($3.4 million vs $3.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | ONCO |
|---|---|---|
| Share price | $0.417 | $0.6543 |
| Market cap | $3.16M | $3.43M |
| 1-day change | -7.37% | +9.56% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-0.44 | $310.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.81 | $207.00 |
| 52-week low | $0.41 | $0.58 |
| Distance from 52-week high | -76.96% | -99.68% |
| Average volume | 29.38K | 2.96M |
| Shares outstanding | 6.73M | 5.24M |
| Employees | 4 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Healthcare · Biotechnology · 4 employees
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Healthcare · Biotechnology · 2 employees
MBIO vs ONCO FAQ
Which is bigger, Mustang Bio or Onconetix?
Onconetix (ONCO) is larger, with a market capitalization of $3.43M compared with $3.16M for Mustang Bio (MBIO).
Are Mustang Bio and Onconetix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.